InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.49
(
-0.26%
)
Bitcoin
60,897.21
(
3.20%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 102189

Monday, 08/23/2010 2:05:35 PM

Monday, August 23, 2010 2:05:35 PM

Post# of 252939

Are you suggesting they should have moved to 2B with Ritonavir boosting?

ITMN’s guidance had been for phase-2b in genotype-1/4 patients to start in 4Q10 (http://finance.yahoo.com/news/InterMune-Reports-Second-prnews-111898175.html?x=0&.v=1 ):

A Phase-2b study of ritonavir-boosted danoprevir plus SOC is expected to begin in the fourth quarter of 2010; the exact timing will be determined with our collaboration partner Roche.

Given that Roche is conducting yet another small PK/safety study, the above timing now seems unlikely.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up